By Dr Alpheus Bingham It has been suggested that the blockbuster business model, which has been the key to big pharma success, is now broken and completely beyond repair. In a truly global and fast changing business world, is it time to examine alternatives to the classic monolithic risk structure and evolve into the 'next […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!